期刊
ONCOTARGET
卷 6, 期 27, 页码 23523-23532出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.4395
关键词
pH low insertion peptide (pHLIP); truncated tissue factor (tTF); tumor vessel targeting; thrombosis
资金
- National Basic Research Plan of China (MoST 973 Program) [2012CB934000]
- National Natural Science Foundation of China [31200752]
- National Natural Science Foundation of China (National Distinguished Young Scientists program) [31325010]
- Key Research Program of Chinese Academy of Sciences [KGZD-EW-T06]
- National Health and Medical Research Council of Australia
- CAS Visiting Professorship Program
Occluding tumor blood supply by delivering the extracellular domain of coagulation-inducing protein tissue factor (truncated tissue factor, tTF) to tumor vasculature has enormous potential to eliminate solid tumors. Yet few of the delivery technologies are moved into clinical practice due to their non-specific tissue biodistribution and rapid clearance by the reticuloendothelial system. Here we introduced a novel tTF delivery method by generating a fusion protein (tTF-pHLIP) consisting of tTF fused with a peptide with a low pH-induced transmembrane structure (pHLIP). This protein targets the acidic tumor vascular endothelium and effectively induces local blood coagulation. tTF-pHLIP, wherein pHLIP is cleverly designed to mimic the natural tissue factor transmembrane domain, triggered thrombogenic activity of the tTF by locating it to the endothelial cell surface, as demonstrated by coagulation assays and confocal microscopy. Systemic administration of tTF-pHLIP into tumor-bearing mice selectively induced thrombotic occlusion of tumor vessels, reducing tumor perfusion and impairing tumor growth without overt side effects. Our work introduces a promising strategy for using tTF as an anti-cancer drug, which has great potential value for clinical applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据